The use of darbepoetin alpha in infants

Among the somatic pathology in young children, the most common is anemic syndrome. Until recently, the commonest method for correction of anemia was hemotransfusion, which allows to restore normal hemoglobin quickly, but has the high risk of complications. The main disadvantage of this method is the...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Shchegolev, G. Z. Sufianova, A. A. Sufianov, N. E. Ivanova, M. S. Khlestkina
Format: Article
Language:Russian
Published: Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University) 2019-06-01
Series:Сеченовский вестник
Subjects:
Online Access:https://www.sechenovmedj.com/jour/article/view/105
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850050740468318208
author A. V. Shchegolev
G. Z. Sufianova
A. A. Sufianov
N. E. Ivanova
M. S. Khlestkina
author_facet A. V. Shchegolev
G. Z. Sufianova
A. A. Sufianov
N. E. Ivanova
M. S. Khlestkina
author_sort A. V. Shchegolev
collection DOAJ
description Among the somatic pathology in young children, the most common is anemic syndrome. Until recently, the commonest method for correction of anemia was hemotransfusion, which allows to restore normal hemoglobin quickly, but has the high risk of complications. The main disadvantage of this method is the short - term positive effect and necessity of repeating donor red blood cell transfusions to prevent rapid progression of anemia. The currently available alternative is the use of an erythropoiesis - stimulating agent, which increases the level of hemoglobin and red blood cells in the blood by stimulating of erythropoiesis in the bone marrow. Modern erythropoiesis - stimulating agent and anti - anemic drug, registered in Russian Federation, is darbepoetin alpha. When developing this drug, a new approach was used to increase the number of sialic acid residues and the degree of glycolysis. This helped to achieve an optimal ratio between the activity and the half - life period of the drug and made possible to prescribe it with longer intervals between injections. Currently, there is evidence of effective and safe use of darbepoetin alpha in premature infants with low body weight, anemia, encephalopathy and chronic kidney disease.
format Article
id doaj-art-a5fc19c09ad74639b9b48eec869210d3
institution DOAJ
issn 2218-7332
2658-3348
language Russian
publishDate 2019-06-01
publisher Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
record_format Article
series Сеченовский вестник
spelling doaj-art-a5fc19c09ad74639b9b48eec869210d32025-08-20T02:53:22ZrusFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Сеченовский вестник2218-73322658-33482019-06-01102636910.47093/22187332.2019.2.63-69104The use of darbepoetin alpha in infantsA. V. Shchegolev0G. Z. Sufianova1A. A. Sufianov2N. E. Ivanova3M. S. Khlestkina4Military Medical AcademyTyumen State Medical UniversityFederal Center of Neurosurgery; Sechenov First Moscow State Medical University (Sechenov University)Federal Center of NeurosurgeryTyumen State Medical University; Federal Center of NeurosurgeryAmong the somatic pathology in young children, the most common is anemic syndrome. Until recently, the commonest method for correction of anemia was hemotransfusion, which allows to restore normal hemoglobin quickly, but has the high risk of complications. The main disadvantage of this method is the short - term positive effect and necessity of repeating donor red blood cell transfusions to prevent rapid progression of anemia. The currently available alternative is the use of an erythropoiesis - stimulating agent, which increases the level of hemoglobin and red blood cells in the blood by stimulating of erythropoiesis in the bone marrow. Modern erythropoiesis - stimulating agent and anti - anemic drug, registered in Russian Federation, is darbepoetin alpha. When developing this drug, a new approach was used to increase the number of sialic acid residues and the degree of glycolysis. This helped to achieve an optimal ratio between the activity and the half - life period of the drug and made possible to prescribe it with longer intervals between injections. Currently, there is evidence of effective and safe use of darbepoetin alpha in premature infants with low body weight, anemia, encephalopathy and chronic kidney disease.https://www.sechenovmedj.com/jour/article/view/105anemiaerythropoiesisdarbepoetin alfapediatricsinfantspremature infants
spellingShingle A. V. Shchegolev
G. Z. Sufianova
A. A. Sufianov
N. E. Ivanova
M. S. Khlestkina
The use of darbepoetin alpha in infants
Сеченовский вестник
anemia
erythropoiesis
darbepoetin alfa
pediatrics
infants
premature infants
title The use of darbepoetin alpha in infants
title_full The use of darbepoetin alpha in infants
title_fullStr The use of darbepoetin alpha in infants
title_full_unstemmed The use of darbepoetin alpha in infants
title_short The use of darbepoetin alpha in infants
title_sort use of darbepoetin alpha in infants
topic anemia
erythropoiesis
darbepoetin alfa
pediatrics
infants
premature infants
url https://www.sechenovmedj.com/jour/article/view/105
work_keys_str_mv AT avshchegolev theuseofdarbepoetinalphaininfants
AT gzsufianova theuseofdarbepoetinalphaininfants
AT aasufianov theuseofdarbepoetinalphaininfants
AT neivanova theuseofdarbepoetinalphaininfants
AT mskhlestkina theuseofdarbepoetinalphaininfants
AT avshchegolev useofdarbepoetinalphaininfants
AT gzsufianova useofdarbepoetinalphaininfants
AT aasufianov useofdarbepoetinalphaininfants
AT neivanova useofdarbepoetinalphaininfants
AT mskhlestkina useofdarbepoetinalphaininfants